In mice with NAFLD-HCC, the supplementation of Lactobacillus acidophilus, through the action of the metabolite valeric acid, which binds to the hepatocyte surface GPR41/43 receptor to inhibit the Rho-GTPase pathway, inhibited NAFLD-HCC [280]. Here, FFAR3 is linked to metabolic dysfunction-associated steatotic liver disease.